Therapeutic management in ambulatory elderly patients with atrial fibrillation: The S.AGES cohort

Journal of Nutrition, Health and Aging

Volumn 19, Issue 2, 2015, Pages 219-227

  Hanon, O ^a,b   Vidal, J S ^a,b   Pisica Donose, G ^a,b   Benattar Zibi, L ^c   Bertin, P ^d   Berrut, G ^e   Corruble, E ^f   Derumeaux, G ^g   Falissard, B ^f   Forette, F ^b,h   Pasquier, F ⁱ   Pinget, M ^j   Ourabah, R ^k   Becquemont, L ^l   Danchin, N ^m  

^a Paris Descartes University   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ORPEA CLINEA   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e CHU DE NANTES   (France)

^f Universite Paris Sud   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h Paris   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k UNIVERSITÉ PARIS SACLAY   (France)

^l BICÊTRE HOSPITAL   (France)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

anticoagulation; Atrial fibrillation; elderly; vitamin K antagonists

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; VITAMIN K GROUP;

AGED; AMBULATORY CARE; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CHADS2 SCORE; COGNITION; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DRUG USE; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; HEMORRHAGE; RISK; STATISTICAL MODEL; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; PLATELET AGGREGATION INHIBITORS; RISK; THROMBOEMBOLISM; VITAMIN K;

EID: 84925516138     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-015-0444-9     Document Type: Article

References (31)

1. Heeringa J, van der Kuip DAM, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–953.
2. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.
3. Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429.
4. Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–2747.
5. Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297–305.
6. Mant J, Hobbs FDR, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.
7. Rash A, Downes T, Portner R et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36:151–156.
8. Ogilvie IM, Newton N, Welner SA et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645.e4.
9. Becquemont L, Benattar-Zibi L, Bertin P et al. National observatory on the therapeutic management in ambulatory care patients aged 65 and over, with type 2 diabetes, chronic pain or atrial fibrillation. Therapie. 2013;68:265–283.
10. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
11. Katz S, Ford AB, Moscowitz RW et al. Studies of Illness in the Age. The index of ADL: a Standardized Measure of the Biological and Psychosocial Function. JAMA. 1963;185:914–919.
12. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–186.
13. Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982–1983;17:37–49.
14. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870.
15. Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–272.
16. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–719.
17. Lip GYH, Frison L, Halperin JL et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–180.
18. Touze E, Cambou J, Ferrieres J et al. Antithrombotic management after an ischemic stroke in French primary care practice: results from three pooled cross-sectional studies. Cerebrovasc Dis. 2005;20:78–84.
19. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.
20. Ghaswalla PK, Harpe SE, Slattum PW. Warfarin use in nursing home residents: results from the 2004 national nursing home survey. Am J Geriatr Pharmacother. 2012;10:25–36.e2.
21. Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423–434.
22. Nieuwlaat R, Capucci A, Lip GYH et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018–3026.
23. Lip GYH, Laroche C, Dan GA et al. ‘Real-world’ antithrombotic treatment in atrial fibrillation: the EURObservational Research Programme Atrial Fibrillation General Pilot survey. Am J Med. 2014;:Forthcoming.
24. Cohen A, Dallongeville J, Durand-Zaleski I et al. Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis. 2010;103:376–387.
25. Kirchhof P, Ammentorp B, Darius H et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2013;:.
26. Friberg L, Hammar N, Ringh M et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J. 2006;27:1954–1964.
27. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.
28. Hylek EM, Evans-Molina C, Shea C et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–2696.
29. Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med. 2013;137:1286–1295.
30. Mant JWF, Richards SH, Hobbs FDR et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord. 2003;3:9.
31. Moroney JT, Tseng CL, Paik MC et al. Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. J Am Geriatr Soc. 1999;47:824–829.